Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Avidity Biosciences Inc (RNA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RNA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 318.67% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.80B USD | Price to earnings Ratio - | 1Y Target Price 66.69 |
Price to earnings Ratio - | 1Y Target Price 66.69 | ||
Volume (30-day avg) 1441455 | Beta 1.02 | 52 Weeks Range 21.56 - 56.00 | Updated Date 04/1/2025 |
52 Weeks Range 21.56 - 56.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4069.63% |
Management Effectiveness
Return on Assets (TTM) -21.61% | Return on Equity (TTM) -33.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2053971125 | Price to Sales(TTM) 348.6 |
Enterprise Value 2053971125 | Price to Sales(TTM) 348.6 | ||
Enterprise Value to Revenue 188.49 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 120212000 | Shares Floating 92698110 |
Shares Outstanding 120212000 | Shares Floating 92698110 | ||
Percent Insiders 5.03 | Percent Institutions 107.33 |
Analyst Ratings
Rating 4.64 | Target Price 68.27 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences Inc. was founded in 2012. The company focuses on developing Antibody Oligonucleotide Conjugates (AOCs) as a new class of precision medicines. It has progressed from preclinical research to clinical-stage development in a relatively short time, focusing on addressing unmet needs in muscular diseases and other serious conditions.
Core Business Areas
- AOC Platform Development: Development of Antibody Oligonucleotide Conjugates (AOCs) for targeted delivery of oligonucleotides to tissues.
- Therapeutic Programs: Development of AOC therapies for muscular dystrophies (DM1, DMD) and other rare diseases.
Leadership and Structure
Avidity Biosciences is led by a management team with experience in drug development and biotechnology. The company has a board of directors providing strategic oversight. Organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- AOC 1001 (DM1 Program): AOC 1001 is Avidity's lead clinical program targeting myotonic dystrophy type 1 (DM1). This targets the Dystrophia Myotonica Protein Kinase (DMPK) mRNA. Early clinical data has shown promising results. Market share is not yet applicable, as the product is in clinical development. Competitors include pharmaceutical companies developing treatments for DM1, such as Ionis Pharmaceuticals (IONS).
- DMD Programs (Duchenne Muscular Dystrophy): Avidity has multiple preclinical programs targeting Duchenne Muscular Dystrophy (DMD) using its AOC platform. Market share is not yet applicable, as the products are in preclinical development. Competitors in the DMD space include Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and innovative, with a focus on developing new therapies for unmet medical needs. There is a growing emphasis on precision medicine and targeted therapies, where Avidity's AOC platform is well-positioned.
Positioning
Avidity is positioned as a leader in the development of AOC therapeutics, a novel approach to oligonucleotide delivery. Its competitive advantage lies in its proprietary AOC platform and its focus on challenging targets in muscular diseases.
Total Addressable Market (TAM)
The TAM for muscular dystrophies and related rare diseases is estimated to be in the billions of dollars. Avidity is positioned to capture a significant portion of this TAM if its AOC therapies are successful.
Upturn SWOT Analysis
Strengths
- Proprietary AOC platform technology
- Strong preclinical and early clinical data
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Clinical development risk
- Reliance on AOC platform success
- Limited commercial infrastructure
- High cash burn rate
Opportunities
- Expansion of AOC platform to other therapeutic areas
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals for AOC therapies
Threats
- Clinical trial failures
- Competition from other biotechnology companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- IONS
- SRPT
- SLDB
Competitive Landscape
Avidity's AOC platform offers a differentiated approach to oligonucleotide delivery compared to traditional methods used by competitors. However, competitors have established products and commercial infrastructure.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Avidity's historical growth has been characterized by the advancement of its AOC platform and therapeutic programs through preclinical and clinical development.
Future Projections: Future growth is dependent on the success of its clinical programs and the expansion of its AOC platform. Analyst estimates vary, but generally project significant revenue growth if AOC therapies are approved.
Recent Initiatives: Recent initiatives include advancing AOC 1001 into later-stage clinical trials, expanding the DMD program, and exploring new therapeutic targets for the AOC platform.
Summary
Avidity Biosciences is a development stage company with a novel AOC platform that has shown promise in early clinical trials. The company's future success hinges on positive clinical trial outcomes and the expansion of its platform. While it faces competition and development risks, its unique technology positions it well in the precision medicine landscape.
Similar Companies
- IONS
- SRPT
- ALNY
- CRSP
Sources and Disclaimers
Data Sources:
- Avidity Biosciences Inc. company website
- SEC Filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may be subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.